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ABSTRACT: The essential biological roles played by
glycosidases, coupled to the diverse therapeutic beneﬁts of
pharmacologically targeting these enzymes, provide consid-
erable motivation for the development of new inhibitor classes.
Cyclophellitol epoxides and aziridines are recently established
covalent glycosidase inactivators. Inspired by the application of
cyclic sulfates as electrophilic equivalents of epoxides in
organic synthesis, we sought to test whether cyclophellitol
cyclosulfates would similarly act as irreversible glycosidase
inhibitors. Here we present the synthesis, conformational
analysis, and application of novel 1,6-cyclophellitol cyclo-
sulfates. We show that 1,6-epi-cyclophellitol cyclosulfate (α-cyclosulfate) is a rapidly reacting α-glucosidase inhibitor whose 4C1
chair conformation matches that adopted by α-glucosidase Michaelis complexes. The 1,6-cyclophellitol cyclosulfate (β-
cyclosulfate) reacts more slowly, likely reﬂecting its conformational restrictions. Selective glycosidase inhibitors are invaluable as
mechanistic probes and therapeutic agents, and we propose cyclophellitol cyclosulfates as a valuable new class of carbohydrate
mimetics for application in these directions.
■ INTRODUCTION
The huge diversity of oligosaccharide, polysaccharide, and
glycoconjugate structures found in nature reﬂect their many
roles in biological processes. Such diversity is mirrored in the
numerous enzymes that have evolved to degrade these
biopolymers. Hydrolytic carbohydrate degrading enzymes,
glycoside hydrolases or glycosidases, are classiﬁed into over
140 distinct sequence (and hence structural) families in the
CAZy database.1 This classiﬁcation provides a powerful
framework upon which aspects of conformational analysis and
enzyme inhibition can be constructed.
Most retaining glycosidases employ a conserved mechanism,
in which the acetals (occasionally ketals) that make up
interglycosidic linkages are hydrolyzed using two key carboxylic
acid residues (Asp or Glu), which function as catalytic
nucleophile and catalytic acid/base.2 Central to glycosidase
activity are the considerable conformational distortions under-
gone by the sugar substrate throughout the catalytic cycle,
which are necessary to satisfy the stereoelectronic and orbital
overlap requirements for glycoside hydrolysis.3
Upon binding to the enzyme, a retaining glycosidase
substrate in the Michaelis complex initially adopts a
conformation in which the leaving group is axially or
pseudoaxially positioned, allowing for favorable in-line attack
by the catalytic nucleophile. Nucleophilic attack, with
concurrent protonation of the glycosidic oxygen by the catalytic
acid/base, leads to a high-energy state (the transition state, TS)
with considerable oxocarbenium ion character. This transition
state must necessarily adopt a conformation in which C5−O5−
C1−C2 are coplanar, to allow for partial oxocarbenium double
bond development between O5 and C1. Following this
transition state, the substrate forms a covalent intermediate
with the glycosidase nucleophile, which is intercepted by water
(following the reverse conformational itinerary) to liberate free
sugar and enzyme. For retaining α- and β-glucosidases, the
typical conformational itineraries for the Michaelis complex →
TS→ intermediate enzymatic half reactions are 4C1→
4H3
⧧
→
1S3 and
1S3 →
4H3
⧧
→
4C1 respectively (Figure 1a), with the
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4H3 TS conformation common to both α- and β-glucosi-
dases.4−7
Mimicry of transition state features is a powerful strategy for
the design of enzyme inhibitors, and thus the majority of
competitive glycosidase inhibitors bind by virtue of mimicking
either the positive charge or the conformational shape of the
transition state.3,8,9 Conformational mimicry can also aid the
reaction of irreversible covalent glycosidase inhibitors,10 such as
cyclitol epoxides and aziridines.10−12 The natural product,
cyclophellitol (1), and its synthetic analogue, cyclophellitol
aziridine (2), are glucose conﬁgured inhibitors, which mimic
the 4H3 conformation adopted by retaining β-glucosidase
substrates in their transition state.3,13,14 Upon binding to the
enzyme active site, nucleophilic attack by the catalytic
nucleophile residue opens the epoxide or aziridine ring,
irreversibly inhibiting the enzyme via formation of a covalent
enzyme−cyclophellitol (aziridine) adduct.
In general, reactive cyclophellitol analogues, locked into TS-
like conformations, are rapid irreversible inactivators of
retaining glycosidases.12,15,16 We recently demonstrated that
replacement of the cyclophellitol epoxide or aziridine ring by a
nonhydrolyzable cyclopropane also yields reversible glycosidase
inhibitors with micromolar to nanomolar aﬃnity.9 Thus,
conformation, rather than just electrophilic reactivity, may
make a substantial contribution to the inhibitory potency of
cyclophellitol analogues.
Given the success of reactive sugar epoxides and aziridines as
conformationally enhanced retaining glycosidase inactiva-
tors,10,12,17 we sought to expand the concept to other
electrophilic species. Cyclic sulfate electrophiles are often
used in synthetic organic chemistry as equivalents of epoxides
in nucleophilic additions, sometimes showing superior
reactivity and regioselectivity.18 We therefore sought to test if
cyclophellitol conﬁgured cyclosulfates could act as a new class
of covalent glycosidase inhibitors. Speciﬁcity for “α” and “β”
enzymes can be conferred simply through choice of the
appropriately conﬁgured cyclosulfate. We additionally reasoned
that substitution of the epoxide in 1 and 3 by a 1,2-cis-cyclic
sulfate should yield compounds favoring a 4C1 conformation.
“α-Conﬁgured” 1,6-epi-cyclophellitol cyclosulfate 5 (hereafter
referred to as α-cyclosulfate) should match, conformationally,
the 4C1 Michaelis complex conformation of substrates for α-
glucosidases and thus be readily poised for in-line nucleophilic
attack by the enzyme, yielding a rapid and potent irreversible
inhibitor. In contrast, a “β-conﬁgured” 1,6-cyclophellitol
cyclosulfate 6 (β-cyclosulfate) locked into a 4C1 conformation
would likely disfavor reactivity on retaining β-glucosidases,
whose Michaelis complex is 1S3.
Here, we present the synthesis of a panel of 1,6-cyclophellitol
cyclosulfates which favor 4C1 chair conformations. α-Cyclo-
sulfate 5 irreversibly inhibits retaining α-glucosidases with
aﬃnity on a par with 1,6-epi-Cyclophellitol aziridine 4, whereas
β-cyclosulfate 6 is a substantially weaker β-glucosidase inhibitor
compared to its cognate aziridine 2. 3-D structures of covalent
adducts from both “α” and “β” cyclosulfates, bound to
representative α- and β-glucosidases, combined with inhibitory
kinetic studies and competitive activity based protein proﬁling
(ABPP), demonstrate the high speciﬁcity and active center−
nucleophile reactivity of these molecules.
The development of selective inhibitors of carbohydrate
processing enzymes is of major interest both for the
understanding of biological processes involved in glycan
processing and in the discovery of new therapeutics.19 Only
minor advances have been observed regarding the development
of new irreversible glycosidase inhibitors since the discovery of
cyclophellitol20 (aziridines)21 or 5-ﬂuoro-22 and 2-deoxy-2-
ﬂuoro-23 glycosides, the latter some 30 years ago.24 Cyclo-
phellitol cyclosulfates thus provide a conceptually novel and
Figure 1. Conformational itinerary of retaining glucosidase reaction pathways and conformation of covalent inhibitors. (a) Reaction itineraries of
retaining β-glucosidases and retaining α-glucosidases, showing conformations of the Michaelis complex, transition state, and covalent intermediates.
(b) Structures of cyclophellitol (1), cyclophellitol aziridine (2), 1,6-epi-cyclophellitol (3), 1,6-epi-cyclophellitol aziridine (4), α-cyclosulfate (5), and
β-cyclosulfate (6).
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powerful tool for further study of glycosidases in health and
disease.
■ RESULTS AND DISCUSSION
Conformational Free Energy Landscapes of Cyclo-
phellitol Cyclosulfates. Cyclophellitol cyclosulfates 5 and 6
were conceived as putative inhibitors of retaining glucosidases.
To determine the likely conformations of these molecules, we
ﬁrst calculated their conformational free energy landscapes
(FELs) using ab initio metadynamics (Supporting Informa-
tion).25 For both 5 and 6, the calculated ground state
conformation was centered at 4C1, with a wide energy
minimum expanding toward the 2H3−E3−
4H3 region (Figure
2a).
We reasoned that the conformational preference of 5 should
render it a potent inactivator of α-glucosidases, as its 4C1
conformation matches that of a typical α-glucosidase Michaelis
complex, with the 4H3 TS conformation also energetically
accessible. In contrast, 6 should not be able to access the 1S3 β-
glucosidase Michaelis complex conformation, although the 4H3
TS conformation could still be accessible. Thus, while 6 may
still inhibit β-glucosidases, it should do so with less potency
compared to 5 vs α-glucosidases.
Synthesis of Cyclic Sulfates 5 and 6. Key intermediate 7
was synthesized from D-xylose in nine steps as optimized in our
group based on the total synthesis of cyclophellitol 1 by
Madsen and co-workers (Figure 3a).26,27 Benzylation of the
free alcohols in 7 yielded alkene 8, which was oxidized
(ruthenium trichloride/sodium periodate) to aﬀord a mixture
of cis diols 9 and 10. Compound 10, emulating α-glucopyrano-
sides in conﬁguration, was obtained pure after silica gel column
chromatography, whereas β-analogue 9 necessitated recrystal-
lization from methanol and diethyl ether in order to obtain
homogeneous material. Generation of the cyclic sulﬁtes by
treatment of thionyl chloride and subsequent oxidation gave
perbenzylated cyclic sulfates 11 and 12, the benzyl ethers of
which were removed by hydrogenolysis using catalytic
palladium on carbon to aﬀord compounds 5 and 6. In line
with FEL calculations, analysis of experimental J-coupling
values for compounds 5 and 6 showed that these analogues
indeed adopt a 4C1 conformation in solution (Table S1).
In Vitro Inhibition of α- and β-Glucosidases and
Kinetic Studies. To establish the activity of cyclosulfates 5 and
6 in relation to their calculated conformations, we assessed their
ability to inhibit representative α- and β-glucosidases compared
to cyclophellitol epoxides and aziridines 1−4, utilizing both
puriﬁed glycosidases and human cell/tissue lysates.
We ﬁrst tested inhibition against human β-glucosidases
GBA1 (recombinant Cerezyme protein from Genzyme,
classiﬁed into the CAZy glycoside hydrolase family GH30)
and GBA2 (GBA2 overexpressing HEK293T lysate, family
GH116), and α-glucosidases GAA (recombinant Myozyme
from Genzyme, family GH31) and GANAB (Pompe disease
ﬁbroblast lysates, family GH31; Table 1). Consistent with our
previous ﬁndings, cyclophellitol 1 and cyclophellitol aziridine 2
were potent inhibitors of GBA1 and GBA2, and 1,6-epi-
cyclophellitol 3 and 1,6-epi-cyclophellitol aziridine 4 inhibited
GAA and GANAB.10,17,28 In line with our predictions regarding
Michaelis complex mimics as strong retaining glycosidase
inhibitors, α-cyclosulfate 5 proved to be a potent nanomolar α-
glucosidase inhibitor (IC50 82 nM vs GAA; 29 nM vs GANAB)
with no reactivity toward β-glucosidases. In contrast, β-
cyclosulfate 6 was only a modest inhibitor of β-glucosidases
(IC50 119 μM for GBA1 and 58 μM for GBA2). IC50s
determined against representative recombinant bacterial
glucosidases (β-glucosidases from Thermotoga maritima,
TmGH1,3,29 and Thermoanaerobacterium xylanolyticum,
TxGH116;30 α-glucosidase from Cellvibrio japonicus,
CjAgd31B10,31) showed the same trend as for the human
enzymes: strong inhibition by 5, and poor inhibition by 6
(Table S2). To conﬁrm that 5 and 6 were stable under the
acidic conditions utilized for these enzymatic assays, the
solvolytic stability of these compounds in McIlvaine buﬀer
pH 4.0 was assessed by NMR. We observed no spontaneous
hydrolysis after 24 h for either 5 or 6 (Figure S2).
We next determined kinetic parameters of inhibition by 1−6
against recombinant human GBA1 and GAA, as well as
bacterial β-glucosidase TmGH1 (Table 2, Figure S3).32
Epoxides 1 and 3 irreversibly inhibited GBA and GAA, with
initial binding constants (KI) of 9.2 μM and 1.4 mM, and
inactivation rate constants (kinact) of 0.7 and 0.5 min
−1
respectively. Consistent with their greater reactivity, aziridines
2 and 4 inhibited GBA and GAA considerably faster than
epoxides (full inhibition typically within 30 s at higher
Figure 2. Conformational free energy landscapes of cyclosulfates 5 and
6. Cyclosulfates 5 (a) and 6 (b) adopt 4C1 ground state conformations,
with a broad energy minimum extending toward 4H3. The x and y axes
of each graph correspond to the φ and θ Cremer−Pople puckering
coordinates (in degrees), respectively. Isolines are 1 kcal/mol.
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concentrations), limiting us to measuring a combined kinact/KI
ratio for these molecules.
α-Cyclosulfate 5 displayed rapid pseudo ﬁrst order inhibition
kinetics against GAA (kinact/KI = 64 min
−1 mM−1), comparable
to 1,6-epi-cyclophellitol aziridine 4 (Figure 3b,c, Table 2),
illustrating the potency of α-conﬁgured cyclosulfates locked in a
Michaelis complex conformation favoring nucleophilic inter-
ception. Conversely, irreversible inhibition of GBA1 by 6 was
several orders of magnitude slower (KI = 3.6 mM; kinact = 0.015
min−1; kinact/KI = 4.33 × 10
−3 min−1 mM−1), suggesting a
limited ability of this molecule to adopt the 1S3 conformation
required for nucleophilic attack and β-glucosidase reactivity.
Comparison of KI values for 6 and 1 against GBA1 also showed
initial binding of 6 to the enzyme to be substantially weaker
compared to 1 (3.5 mM and 9 μM respectively). These values
are consistent with the tighter binding aﬃnities often displayed
by TS shape analogues compared to molecules locked into
other conformations.
Interestingly, while irreversible inhibition by aziridines 2 and
4 was largely speciﬁc toward α- or β-glucosidases respectively,
these molecules were also observed to be less speciﬁc reversible
inhibitors for glucosidases of the opposite anomeric speciﬁcity
(competitive inhibition of GAA by 2, KI = 9.6 μM; competitive
inhibition of GBA1 by 4, KI = 6.8 μM; Table 2). We reason that
the common 4H3 transition state utilized by both α- and β-
glucosidases may allow these enzymes to bind aziridines of
either “anomeric” conﬁguration. Thus, the conformational
preference of cyclophellitol cyclosulfates presents an advantage
in speciﬁcity when compared to aziridine type inhibitors, by
virtue of mimicking a reactive conformation receptive to
nucleophilic attack, not shared between α- or β-glucosidases.
Structural Characterization of Enzyme−Cyclosulfate
Interactions. Because of the key role of conformation in the
contrasting inhibitory potency of cyclophellitol cyclosulfates
Figure 3. Synthesis of cyclophellitol cyclosulfates 5 and 6, and inactivation of GAA by compound 5. (a) Compounds 5 and 6 were prepared from
cyclohexene 11. Reagents and conditions: (i) BnBr, TBAI, NaH, DMF, rt, 18 h, 70%; (ii) RuCl3, NaIO4, EtOAc, ACN, 0 °C, 2 h (13, 39%; 14,
26%); (iii) (a) SOCl2, Et3N, DCM, 0 °C, (b) RuCl3, NaIO4, CCl4, ACN, 0 °C, 3 h (15, 59%; 16, 62%); (iv) H2, Pd/C, MeOH, rt, 18 h (5, 71%; 6,
72%). (b) Semilogarithmic plots of residual activity of GAA versus time at 9, 8, 7, 6, 5, 4, 3, and 2 μM α-cyclosulfate 5. (c) Plot of pseudo ﬁrst order
rate constants from panel c vs concentration of 5.
Table 1. Enzyme Inhibition Eﬃcacy of Compounds 1−6a
IC50
β-glucosidase α-glucosidase
compd GBA1 GBA2 GAA GANAB
1 165 ± 4 nM 139 ± 60 nM >100 μM >100 μM
2 304 ± 5 nM 14 ± 1 nM >100 μM >100 μM
3 >100 μM >100 μM 15 ± 2 μM >100 μM
4 21 ± 1 μM >100 μM 38 ± 3 nM 1.4 ± 0.1 μM
5 >100 μM >100 μM 82 ± 1 nM 29 ± 2 nM
6 119 ± 9.8 μM 58 ± 4.5 μM >100 μM >100 μM
aApparent IC50 values for in vitro inhibition of GBA1, GBA2, GAA,
and GANAB. Reported values are mean ± standard deviation from 3
technical replicates.
Table 2. Kinetic Parameters of Compounds 1−6a
β-glucosidase GBA1 α-glucosidase GAA
compd kinact (min
−1) KI kinact/KI (min
−1 mM−1) kinact (min
−1) KI kinact/KI (min
−1 mM−1)
1 0.72 9.2 μM 77.7 >500 μM
2 nd nd 19.0 9.6 μM*
3 >500 μM 0.52 1.4 mM 0.37
4 6.8 μM* nd nd 58.0
5 >500 μM nd nd 64.3
6 0.015 3.6 mM 4.3 × 10−3 >500 μM
aInactivation rates and inhibition constants (kinact and KI) for human recombinant β-glucosidase GBA1 and α-glucosidase GAA; nd, not determined
due to fast inhibition; *, reversible inhibition observed.
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against α- vs β-glucosidases, we set out to structurally
characterize the conformational itinerary of 5 and 6 when
reacted with representative bacterial glucosidases.
Crystal structures of 5 in complex with the GH31 α-
glucosidase/tranglycosidase CjAgd31B from Cellvibrio japoni-
cus10,31 were obtained by soaking crystals of wild type
CjAgd31B with 5. We observed density for a covalent adduct
bound to the enzyme nucleophile (Asp412) corresponding to
ring opened cyclosulfate in a 1S3 conformation (Figure 4a),
matching the conformation previously observed for reacted
aziridine 4,10 as well as a complex of CjAgd31B reacted with 5-
ﬂuoro-α-glucosyl ﬂuoride31 (Figure 4b; PDB codes 5I24 and
4BA0 respectively). Structures of unreacted 5 were also
obtained in complex with an inactive D412N nucleophile
mutant of CjAgd31B. Density for unreacted 5 in the CjAgd31B
active site matched a 4C1 conformation as predicted by FEL
calculations and NMR analysis (Figure 4a), demonstrating that
5 indeed binds to α-glucosidases as a conformational Michaelis
complex analogue, allowing unimpeded access for in-line attack
by the enzyme nucleophile. Diﬀerence density in the active site
of CjAgd31B D412N after soaking with 4 corresponded to an
unreacted cyclophellitol aziridine in 4H3 conformation (Figure
4b), consistent with this molecule acting as a TS shape mimic
when unreacted.
We then utilized the β-glucosidase from Thermoanaerobac-
trium xylanolyticum TxGH116 for structural studies with 6. Due
to its slow reactivity as an irreversible β-glucosidase inhibitor,
we were able to capture an unreacted complex of 6 with crystals
of wild type TxGH116 by utilizing shorter ligand soaking times.
After 10−20 min soaks, a single molecule of unreacted 6 was
observed within the active site of TxGH116, adopting a 4C1
conformation in line with FEL calculations and NMR spectra.
This 4C1 conformation renders the equatorial C1−O bond of 6
poorly poised for in-line attack by the enzyme nucleophile
Glu441, thus providing a structural rationale for the slow
reactivity of this inhibitor against β-glucosidases. Extended
ligand soaking times (∼24 h) were required to produce a
reacted covalent complex of 6 with TxGH116. Reacted 6 was
observed bound to the TxGH116 catalytic nucleophile
(Glu540) in a 4C1 covalent intermediate conformation,
consistent with the typical retaining β-glucosidase conforma-
tional itinerary utilized by this enzyme and matching the 4C1
conformation previously observed for reacted 2-deoxy-2-
ﬂuoroglucoside (PDB code 5BX2).
We also investigated the structural basis for “oﬀ-target”
inhibition by cyclophellitol aziridines, which we had observed
to competitively inhibit glucosidases of “opposing” anomeric
speciﬁcity. A crystal structure of 2 in complex with CjAgd31B
showed a single molecule of inhibitor occupying the enzyme
active site, with the aziridine nitrogen H-bonding to the
catalytic nucleophile carboxylate (∼2.6 Å between aziridine N
and Asp O Oδ; Figure S5). The presence of an unreacted
aziridine between the nucleophile and the plane of the cyclitol
ring induces an E3 conformation for the inhibitor, rather than
the 4H3 observed for an unreacted “correct” aziridine (Figure
4b). It is likely that the competitive inhibition of α-glucosidases
by 4 is based around a similar interaction between the
unreacted aziridine nitrogen and catalytic nucleophile.
Competitive ABPP of α-Glucosidases by Cyclosulfate
5. To assess the utility of cyclosulfates as enzyme inhibitors in
complex biological samples, we examined the activity and
selectivity of α-cyclosulfate 5 by competitive activity-based
protein proﬁling (ABBP), against 1310 (Figure S1), a
Figure 4. Structures of reacted 4 and 5 bound to wild type CjAgd31B
and reacted 6 bound to wild type TxGH116. (a) Unreacted (left) and
reacted (right) 5 in complex with CjAgd31B D412N nucleophile
mutant and wt CjAgd31B respectively. Unreacted 5 adopts a 4C1 ring
conformation in the active site of CjAgd31B, mimicking the Michaelis
complex conformation of GH31 α-glucosidase substrates. Reacted 5
adopts a 1S3 covalent intermediate conformation. (b) Unreacted (left)
and reacted (right) 4 in complex with CjAgd31B D412N nucleophile
mutant and wt CjAgd31B respectively. Unreacted 4 adopts a 4H3 TS
conformation. Reacted 4 adopts the same 1S3 intermediate
conformation as observed for 5. (c) Unreacted (left) and reacted
(right) β-cyclosulfate 6 with TxGH116. Unreacted 6 in complex with
GH116 β-glucosidase TxGH116 adopts a 4C1 conformation in the
enzyme active site, which is poorly poised for attack by the enzyme
nucleophile Glu441, and thus reacts extremely slowly. (Two
conformations for the enzyme catalytic acid/base Asp593 can be
seen in this complex.) Reacted 6 can be observed after extended
soaking, and also adopts a 4C1 conformation, covalently bound to the
enzyme nucleophile. Electron density for protein side chains is
REFMAC maximum-likelihood/σA-weighted 2Fo − Fc contoured to
0.44−0.51 and 0.40−0.42 electron/Å3 for CjAgd31B and TxGH116
complexes, respectively. Electron density for ligand is Fo − Fc maps
calculated just prior to building in ligand, contoured to 0.17−0.26 and
0.27−0.35 electron/Å3 for CjAgd31B and TxGH116 complexes,
respectively. nuc. = nucleophile; a./b. = acid/base.
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ﬂuorescent retaining α-glucosidase aziridine probe which labels
GAA at pH 4 (isoforms at 70 and 76 kDa) and both isoforms of
GANAB (∼100 kDa) at pH 7.
We ﬁrst preincubated ﬁbroblast lysates with varying
concentrations (1, 0.3, 0.1, and 0.03 μM) of 5 for 15, 30, or
60 min at pH 4 or pH 7, and subsequently labeled with 13 (1
μM) for 30 min. SDS−PAGE followed by ﬂuorescence
scanning showed time dependent inhibition of both GAA and
GANAB by 5 at pH 4 and 7 respectively (Figure 5a).
Competitive ABPP in GBA2 and GBA3 overexpressing
HEK293T lysates (GBA2+ and GBA3+) against β-glucosidase
probe 14 (Figure S1) showed no inhibition of retaining β-
glucosidases by 5, demonstrating the high selectivity of this
inhibitor class (Figure S5).
Acarbose, miglitol, and voglibose are α-glucosidase inhibitors
(AGIs) widely used in diabetes mellitus type II patients. These
inhibitors delay the absorption of carbohydrates, decrease
postprandial hyperglycemia and hyperinsulinemia, and thus
improve insulin sensitivity and release stress on beta cells.33−35
Prompted by the potential of AGIs as leads for diabetes mellitus
type II drug development, we investigated the inhibition of a
group of key metabolic α-glucosidases in murine gastro-
intestinal tract tissues using competitive ABPP. Our studies
showed that, in addition to GAA and GANAB, 5 inhibited two
α-glucosidases expressed speciﬁcally in intestinal tissue: sucrase-
isomaltase (SIS) and maltase-glycoamylase (MGAM) (Figure
5b). Signiﬁcantly, β-glucosidases lactase-phlorizin hydrolase
(LPH) and GBA1, which are labeled in an oﬀ-target fashion by
Figure 5. In vitro and in situ inhibition of GAA and GANAB. (a) 5 inhibits labeling of GAA and GANAB by ﬂuorescent ABP 13 in ﬁbroblast lysates
in a concentration and time dependent manner. (b) 5 inhibits labeling of several α-glucosidases in mouse intestine lysate by 13. Sucrase-isomaltase
(Sis), maltase-glucoamylase (MGAM), GAA, and GANAB are labeled by 13, as well as some oﬀ-target β-glucosidase labeling (LPH and GBA). α-
Glucosidase labeling can be abrogated by preincubation with 5, while β-glucosidase labeling persists, demonstrating the superior selectivity of 5
compared to 13. (c) In situ inhibition of GAA and GANAB in ﬁbroblasts at pH 4.0 and 7.0 respectively by 5 at incubation times of 2 and 24 h,
followed by labeling of GAA and GANAB by cyclophellitol aziridine Cy5 probe 13. (d) Apparent IC50s for in situ inhibition of GAA and GANAB
enzyme activity by 5. Reported IC50s are mean ± standard deviation from two biological replicates, each with three technical replicates.
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13, are not outcompeted by preincubation with 5, clearly
demonstrating superior selectivity of cyclosulfate inhibitors
compared to aziridines.
Lastly, we investigated whether α-cyclosulfate 5 is able to
cross the cell membrane. Human ﬁbroblasts were exposed to
varying concentrations (10, 1, 0.1, 0.01, 0.001, and 0 μM) of 5
for 2 and 24 h, followed by extensive washing and lysate
preparation. Lysates were incubated with 13 (0.5 μM) for 30
min and then separated by SDS−PAGE, followed by
ﬂuorescence scanning. Time dependent abrogation of ABP
13 ﬂuorescence was observed, illustrating that 5 could cross the
cell membrane to act in situ as α-glucosidase inhibitor (Figure
5c). Loss of ABP labeling was also accompanied by a
corresponding loss of α-glucosidase enzymatic activity in
harvested ﬁbroblast lysates. Activity assays utilizing 4-
methylumbelliferyl-α-glucose suggested robust in situ inhibition
of both GAA and GANAB by 5, with IC50s of 3.0 and 1.6 μM
respectively (Figure 5d).
■ CONCLUSION
In this study, we have presented a new class of irreversible
glycosidase inhibitors: cyclophellitol cyclosulfates. We have
shown that their irreversible action is speciﬁc for α- and β-
glucosidases in a manner reﬂecting both the “anomeric”
stereochemistry of the cyclophellitol cyclosulfates and the
conformational itinerary of the target enzyme.
We have demonstrated, through ab initio metadynamics
approaches and 3-D structures of enzyme ligand complexes,
that unreacted α-cyclosulfate 5 favors a 4C1 “Michaelis complex
like” conformation which is perfectly poised for nucleophilic
attack by α-glucosidases utilizing a 4C1 →
4H3 →
1S3
glycosylation itinerary. Thus, 5 is a nanomolar mechanism-
based retaining α-glucosidase inactivator, which follows pseudo
ﬁrst order kinetics, and displays superior selectivity compared
to existing mechanism-based inhibitors due to its unique
conformational behavior. We have also shown that 5 inhibits
the intestinal retaining α-glucosidases SIS, MGAM, GAA, and
GANAB, without aﬀecting β-glucosidases intestinal LPH or
GBA1. Thus, 5, which is also able to cross the cell membrane,
may be a good starting point for the development of agents for
the treatment of type II diabetes.
β-Cyclosulfate 6 also adopts a 4C1 conformation in its
unreacted state, which does not match the 1S3 conformation of
typical β-glucosidase Michaelis complexes. When applied to
retaining β-glucosidases following a 1S3 →
4H3 →
4C1
conformational itinerary, 6 reacts extremely slowly compared
to its congener 5.
FEL calculations show that the ground state conformation of
6 is centered around 4C1, a conformation with an equatorial
C1−O bond that precludes in-line attack from the nucleophile.
Crystal structures of unreacted 6 in complex with β-glucosidase
TxGH116 show that the β-cyclosulfate continues to adopt this
4C1 conformation even within the enzyme active site. However,
FEL calculations also suggest that it is energetically possible for
6 to access a TS-like 4H3 conformation. Transient sampling of
this TS conformation may allow for occasional reaction of 6
with β-glucosidases, as the cyclosulfate adopts a conformation
better suited to nucleophilic attack by the enzyme. However,
the slow rate of irreversible inhibition observed for 6 suggests
that its predominant conformation within the enzyme active
site is one where nucleophilic attack from the enzyme is
disfavored.
The last 10−20 years have provided us a deep appreciation of
reaction coordinates of diverse glycosidases.6,7,10,36 This
conformational canvas inspires the design and application of
chemical species to mimic speciﬁc species along the reaction
coordinate. Much existing work has focused on the design of
noncovalent transition state mimics, or conformationally
restricted species that mimic a species along only certain
reaction trajectories, such as the speciﬁc inhibition of GH47 α-
mannosidases by kifunensine.37,38 Recent years have, however,
seen a resurgence in the development of irreversible enzyme
inhibitors as clinical probes and diagnostics.10,11,16,39 With such
applications in mind, the development of conformationally
restrained irreversible inhibitors primed for nucleophilic attack
through mimicry of the Michaelis complex, coupled to more
electrophilic reaction centers, inspires creation of conceptually
new, potent and selective glycosidase inhibitors. We envision
that our design strategy will also be applied for other
glycosidases, both those following a similar 4C1 →
4H3 →
1S3
conformational itinerary and those following other conforma-
tional trajectories, guided by the conformational preference of
the reaction pathway.
■ MATERIALS AND METHODS
All chemicals were obtained from Sigma-Aldrich, unless
otherwise stated. Pompe disease ﬁbroblasts, HEK293T cells
(ATCC-CRL-3216), and normal ﬁbroblast cell lines were
obtained from the American Type Culture Collection (ATCC)
and transfected for GBA2 and GBA3 overexpression (Support-
ing Information). Cell lines were cultured in DMEM/F-12
(Ham) medium (Invitrogen) supplemented with 10% (v/v)
fetal calf serum (FCS; Sigma) and 1% penicillin/streptomycin
(Sigma). Mouse tissues were isolated according to guidelines
approved by the ethical committee of Leiden University
(DEC#13191). Human recombinant enzymes rGBA1 (Cer-
ezyme) and rGAA (Myozyme) were donated by Genzyme,
GBA2 was overexpressed in HEK293T lysates, and GANAB
was obtained from ﬁbroblasts of Pompe patients diagnosed on
the basis of absence of GAA (Supporting Information).
Bacterial enzymes TmGH1,29 TxGH116,30 and CjAgd31B31
were expressed as previously described. All cell or tissue lysates
were prepared in KPI buﬀer (25 mM potassium phosphate pH
6.5, supplemented with protease inhibitor 1× cocktail (Roche))
via homogenization on ice with SilentCrusher S equipped with
Typ 7 F/S head (30 × 1000 rpm, 3 × 7 s). Lysate protein
concentrations were determined with BCA Protein Assay Kit
(Pierce). Lysates and proteins were stored in small aliquots at
−80 °C until use.
IC50 and Inhibition Kinetics Determination. Detailed
protocols for IC50 and inhibition kinetics measurements can be
found in the Supporting Information.
In brief, apparent IC50 values were determined by
preincubating enzymes with a range of inhibitor concentrations
in a 25 μL volume for 30 min at 37 °C (for human enzymes) or
25 °C (for bacterial enzymes). Following preincubation, 25 μL
of the enzyme−inhibitor mixture was transferred into 100 μL of
the appropriate 4-MU−Glc substrate mixture to determine
residual activity. Reactions were quenched with 1 M NaOH−
glycine (pH 10.3) upon completion, and 4-MU ﬂuorescence
was measured with a LS55 ﬂuorescence spectrophotometer
(PerkinElmer) (λEX 366 nm; λEM 445 nm). IC50 values reported
are the mean values from three technical replicates.
In situ IC50 values were determined by incubating normal
human dermal ﬁbroblasts (grown to conﬂuency) with 5 for 2
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and 24 h. Cells were washed three times with PBS and
harvested by scraping into KPI buﬀer supplemented with 0.1%
(v/v) Triton X-100 and 1× cOmplete protease inhibitor
cocktail (Roche). Residual GAA and GANAB activity was
measured on the basis of hydrolysis of 4-MU−α-Glc at pH 4 or
7. In situ IC50 values are mean values from two biological
replicates, each with 3 technical repeats (Figure 5d).
For kinetics, enzyme and relevant concentrations of inhibitor
were preincubated for 0.5, 2, 3.5, 5, and 8 min for fast inhibitors
and 0.5, 20, 60, 120, 180, 240, and 360 min for slow inhibitors.
At relevant time points, 5 μL of this enzyme−inhibitor mixture
was added to 2,4-DNP−Glc substrate, and release of 2,4-
dinitrophenolate was monitored via absorbance at 400 nm to
determine the rate of hydrolysis after inhibition (V) compared
to a no inhibitor control (V0).
Pseudo ﬁrst order rate constants (kobs) were obtained from a
linear ﬁt of −ln V/V0 against time for each value of [I]. A plot
of kobs against [I] ﬁtted to the hyperbolic equation kobs =
(kinact[I]/KI + [I]) was used to determine kinact and KI. Where
fast inhibition was observed (>50% after 30 s), the kinact/KI
ratio was determined at low values of [I] (≪KI), using the
approximation kobs ≈ kinact[I]/KI, where kinact/KI is the slope of
a linear ﬁt of kobs vs [I]. Where reversible inhibition was
observed (no variation of −ln V/V0 with time), KI was
determined by use of Lineweaver−Burk plots at diﬀerent values
of [I].
Time and Concentration Dependent in Vitro Inhib-
ition of GAA and GANAB. Homogenates of human normal
dermal ﬁbroblast (17.6 μg total protein) were preincubated on
ice for 5 min in 150 mM McIlvaine buﬀer pH 4 or 7 in a total
volume of 10 μL. Samples were then incubated for 15, 30, and
60 min at 37 °C with 2.5 μL inhibitor dilutions in McIlvaine
buﬀer pH 4 or 7 to obtain a ﬁnal concentration of 5, 1.5, 0.5,
0.15, and 0 μM. Afterward, the samples were further incubated
with 2.5 μL of ABP 13 (1 μM), diluted in McIlvaine buﬀer pH
4 or 7 for 30 min at 37 °C. Finally, samples were denatured
with 5 μL of 4× Laemmli sample buﬀer for 5 min at 98 °C, and
resolved by 10% (w/v) SDS−PAGE. Wet slab gels were
subjected to Cy5 ﬂuorescence scaning (Typhoon FLA9500,
GE, λEX ≥ 635 nm, λEM ≥ 665 nm).
In Vitro Inhibition of α-Glucosidases in Mouse
Gastrointestinal Lysate. Mixtures of mouse duodenum,
jejunum, and ileum homogenates containing 40 μg total
protein were incubated on ice for 5 min with McIlvaine buﬀer
at pH 4 or 7, in a total volume of 10 μL. Samples were
subsequently incubated with 2.5 μL of 5 for 1 h at 37 °C at
various inhibitor dilutions in McIlvaine buﬀer at pH 4.0 or 7.0
to obtain a ﬁnal concentration of 150, 50, 15, 5, 1.5, 0.5, 0.15,
0.05, 0.015, 0.005, and 0 μM. Then, the samples were further
incubated with 2.5 μL of 13 (6 μM, diluted in McIlvaine buﬀer
at pH 4.0 or 7.0) for 30 min at 37 °C. Samples were denatured
by boiling with 3.75 μL of 4× Laemmli sample buﬀer for 5 min,
and resolved by 10% (w/v) SDS−PAGE. Wet slab gels were
subjected to Cy5 ﬂuorescence scanning (Typhoon FLA9500,
GE, λEX ≥ 635 nm, λEM ≥ 665 nm).
In Situ inhibition of GAA and GANAB. Human normal
dermal ﬁbroblasts were grown to conﬂuence and in situ treated
with inhibitor 5 at various concentrations (10, 1, 0.1, 0.01,
0.001, and 0 μM) in duplicates for 2 or 24 h. Cells were
harvested by ﬁrst washing three times with PBS and
subsequently lysed with KPI buﬀer (25 mM K2HPO4/
KH2PO4, pH 6.5, 0.1% (v/v) Triton X-100, protease inhibitor
cocktail (Roche)) on ice for 30 min. Homogenates were
collected by scraping, vortexed, and stored at −80 °C. Lysates
containing 4 μg total protein were equilibrated to pH 4 or 7 in
150 mM McIlvaine buﬀer for 5 min on ice, and incubated with
probe 13 (0.5 μM) for 30 min at 37 °C at either pH 4 or 7 in a
total volume of 15 μL. Samples were denatured, resolved by
SDS−PAGE, and subjected to ﬂuorescent scan (Typhoon
FLA9500, GE, λEX ≥ 635 nm, λEM ≥ 665 nm)
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